|
The National Ambulatory Medical Care Survey (NAMCS)
|
Health Survey
|
CDC
|
NCCAM
|
The National Ambulatory Medical Care Survey (NAMCS) is a national survey designed to meet the need for objective, reliable information about the provision and use of ambulatory medical care services in the U.S. Findings are based on a sample of visits to non-federal employed office-based physicians who are primarily engaged in direct patient care. In 2012, a series of questions were added to assess what types of complementary health practices are used physician offices and the referral patterns to complementary health care providers such a chiropractors and acupuncturists.
|
|
The National Committee on Vital and Health Statistics
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS
|
OD/DPCPSI/OBSSR
|
The National Committee on Vital and Health Statistics (NCVHS) serves as the statutory [42 U.S.C. 242k(k)] public advisory body to the Secretary of Health and Human Services in the area of health data and statistics. In that capacity, the Committee provides advice and assistance to the Department and serves as a forum for interaction with interested private sector groups on a variety of key health data issues.
|
|
The NIH Bone Marrow Stromal Cell Transplantation Center
|
Research Initiative
|
FDA
|
NIDCR, CC, NCI, NHLBI, NIAID, NIAMS, NIBIB, NINDS
|
The mission of the NIH Bone Marrow Stromal Cell (BMSC) Transplantation is to develop clinical grade bone marrow stromal cells for use in clinical trials that utilizes the ability of these cells to exert immunomodulatory and immunosuppressive effects that are beneficial for the treatment of a number of diseases and disorders, and to provide assistance to clinical investigators in the preparation of regulatory documents for institutional review boards and the U.S. Food and Drug Administration.
|
|
The Planning Committee for the Third NIH/ORWH Online Class in the Series, "The Science of Sex and Gender in Human Health", entitled "The Influence of Sex and Gender on Disease Expression and Treatment"
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA, OD/DPCPSI/ORWH
|
This online series of courses provides a foundation for sex and gender accountability in medical research and treatment. After completing the courses, researchers, clinicians, and students in the health professions will be able to integrate knowledge of sex and gender differences and similarities into their research and practice.
|
|
The Public Health Service (PHS) Men Who Have Sex With Men (MSM) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NHLBI
|
The Working Group is developing guidelines and strategies to improve HIV/STD programs for men who have sex with men (MSM).
|
|
The Public Health Service (PHS) Review Committee on the Use of Marijuana in Clinical Research
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS, SAMHSA
|
NIMH, NCCAM, NIDA, NINDS
|
Follow-up review of revised application for purchase of research-grade marijuana from NIDA for use in proposed treatment study of refractory post-traumatic stress disorder (PTSD) in military veterans. An addiitonal protocol revision and re-review are planned.
|
|
The U.S. Surgeon General''s Report: The Health Consequences: 50 Years of Progress
|
Other
|
CDC
|
OD/DPCPSI/OBSSR
|
Contributing author to Chapter 15 “Tobacco Control Simulation Models”.
|
|
The United States Renal Data System (USRDS)
|
Resource Development
|
CMS, HRSA
|
NIDDK
|
The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the U.S. The missions of the USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients.
|
|
The World Health Organization (WHO) Planning Committee for the Guidelines on the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIDA
|
These guidelines were produced by the World Health Organization (WHO) Department of Mental Health and Substance Abuse (Management of Substance Abuse unit), in collaboration with the WHO Management of Noncommunicable Diseases Department (MND) and the United Nations Office on Drugs and Crime (UNODC) Prevention, Treatment and Rehabilitation Section (PTRS). The development of these guidelines was coordinated by Vladimir Poznyak and Nicolas Clark under the direction of Shekhar Saxena and in collaboration with Edouard Tursan d''Espaignet and Lubna Bhatti (WHO) and Elizabeth Mattfeld (UNODC).
|
|
Therapeutics for Rare and Neglected Diseases (TRND)/FDA Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCATS
|
A group of Therapeutics for Rare and Neglected Diseases (TRND) staff and U.S. Food and Drug Administration (FDA) staff from the Center for Drug Evaluation and Research (CDER) meet on a semi-monthly basis to discuss projects for the TRND program. The purpose of this working group is to discuss the scientific progress on each project toward the eventual goal of an Investigational New Drug Application for each project. Results of experiments are discussed, and TRND staff takes the feedback of FDA/CDER staff into consideration when developing future project plans.
|